DCM
CBAY

DAFNA Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

DAFNA Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-171,059
Closed -$1.07M – 80
2022
Q4 		$1.07M Sell
171,059
-1,532,176
-90% -$5.82M 0.3% 51
2022
Q3 		$5.96M Sell
1,703,235
-84,334
-5% -$303K 1.6% 20
2022
Q2 		$5.27M Buy
1,787,569
+95,000
+6% +$227K 1.44% 23
2022
Q1 		$5.26M Sell
1,692,569
-95,000
-5% -$299K 1.37% 21
2021
Q4 		$6.04M Buy
1,787,569
+1,263,283
+241% +$4.8M 1.52% 19
2021
Q3 		$1.91M Buy
524,286
+13,900
+3% +$54.8K 0.51% 47
2021
Q2 		$2.23M Buy
510,386
+172,616
+51% +$765K 0.47% 47
2021
Q1 		$1.53M Buy
+337,770
New +$1.82M 0.36% 63
2020
Q3 		– Sell
-165,600
Closed -$578K – 92
2020
Q2 		$578K Buy
+165,600
New +$478K 0.17% 73
2019
Q4 		– Sell
-349,996
Closed -$1.79M – 90
2019
Q3 		$1.79M Hold
349,996
– – 0.67% 37
2019
Q2 		$2.51M Buy
349,996
+71,185
+26% +$806K 0.94% 30
2019
Q1 		$3.7M Sell
278,811
-53,700
-16% -$571K 1.6% 21
2018
Q4 		$2.62M Buy
332,511
+38,000
+13% +$362K 1.3% 26
2018
Q3 		$3.26M Hold
294,511
– – 1.34% 23
2018
Q2 		$3.95M Sell
294,511
-29,332
-9% -$367K 1.85% 18
2018
Q1 		$4.21M Sell
323,843
-37,321
-10% -$464K 2.05% 17
2017
Q4 		$3.32M Sell
361,164
-73,836
-17% -$631K 1.79% 20
2017
Q3 		$3.51M Buy
435,000
+415,933
+2,181% +$2.81M 2.18% 11
2017
Q2 		$110K Sell
19,067
-69,000
-78% -$294K 0.08% 73
2017
Q1 		$379K Buy
+88,067
New +$253K 0.32% 58

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DAFNA Capital Management's CBAY Position: Q1 2023 in Review

DAFNA Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2023, closing a stake of 171,059 shares — an estimated $1.07M sold.

DAFNA Capital Management first reported a position in CBAY in Q1 2017 and held it in 20 quarters. The position peaked at $6.04M in Q4 2021. 139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

  • DAFNA Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2023 after selling out during the quarter.
  • DAFNA Capital Management sold 171,059 Cymabay Therapeutics shares in Q1 2023, an estimated $1.07M.
  • DAFNA Capital Management first reported a position in Cymabay Therapeutics in Q1 2017 and held it in 20 quarters.
  • DAFNA Capital Management's Cymabay Therapeutics position peaked at $6.04M in Q4 2021.
  • 139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on DAFNA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.